Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Positive Technologies shipments in 2023 grew by 74%

3/6/24 POSI

Kamaz plans to expand the line of Compass up to five models

3/6/24 KMAZ

Yandex Nedvizhimost has turned into a classifide with a broad service function

3/6/24 YNDX

Bank Saint-Petersburg reported for 2023 by IFRS

3/6/24 BSPB

Phosagro launched a new fertilizer complex in the Leningrad region

3/6/24 PHOR

Aeroflot received about ₽112 billion in positive effects

3/6/24 AFLT

Gazprom Neft will independently determine the amount of information to be disclosed

3/6/24 SIBN

Government sets additional discount for Yandex

3/6/24 YNDX

Board of Directors of MOEX Group (Moscow Exchange) recommended that dividends be paid for 2023

3/5/24 MOEX

Genetico is ramping up the number of PGT tests

3/5/24 GECO